Resource Summary Report

Generated by ASWG on Aug 15, 2026

Brilliant Violet 785(TM) anti-human CD4

RRID:AB_2564382
Type: Antibody

Proper Citation

BioLegend Cat# 300554, RRID:AB_2564382

Antibody Information

URL: http://antibodyregistry.org/AB_2564382

Proper Citation: BioLegend Cat# 300554, RRID:AB_2564382

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: human

Clone ID: Clone RPA-T4

Antibody ID: AB_2564382

Vendor: BioLegend

Catalog Number: 300554

Alternative Catalog Numbers: 300553

Record Creation Time: 20250820T001010+0000

Record Last Update: 20250820T073319+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD4.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Li Z, et al. (2026) Systematic profiling of SARS-CoV-2 structural protein-specific T cell epitopes in Omicron infections following inactivated vaccination. iScience, 29(3), 114891.

Bracey NA, et al. (2026) Aging restricts maturation of CXCL13+ T follicular helper cells in human immunity. Cell reports, 45(6), 117423.

Galvez NMS, et al. (2026) HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. Immunity, 59(3), 768.

Stetsenko V, et al. (2025) Human CD4+ T cells recognize Mycobacterium tuberculosis-infected macrophages amid broader responses. The Journal of experimental medicine, 222(12).

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. Cell reports. Medicine, 6(7), 102198.

Cimen Bozkus C, et al. (2025) T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome. iScience, 28(8), 113044.

Kim WJ, et al. (2025) Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias. Cell, 188(13), 3422.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905.

Gail DP, et al. (2024) Analyzing human CD4+ T cells activated in response to macrophages infected with Mycobacterium tuberculosis. STAR protocols, 5(1), 102939.

Grünhagel B, et al. (2023) Reduction of IFN-I responses by plasmacytoid dendritic cells in a longitudinal trans men cohort. iScience, 26(11), 108209.

Gail DP, et al. (2023) Mycobacterium tuberculosis impairs human memory CD4+ T cell recognition of M2 but not M1-like macrophages. iScience, 26(9), 107706.

Meyer S, et al. (2023) Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants. Cell reports, 42(1), 111995.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. Cell, 185(8), 1414.

Farhat AM, et al. (2021) Modeling cell-specific dynamics and regulation of the common gamma chain cytokines. Cell reports, 35(4), 109044.

Leylek R, et al. (2020) Chromatin Landscape Underpinning Human Dendritic Cell Heterogeneity. Cell reports, 32(12), 108180.